Role of allogeneic stem cell transplantation in multiple myeloma

Research output: Contribution to journalReview article

3 Scopus citations

Abstract

Multiple myeloma remains incurable despite the use of high-dose therapy and autologous stem cell transplantation and the introduction of novel agents with high response rates. The use of an uncontaminated stem cell graft and the presence of a graft-versus-myeloma effect led to the use of allogeneic stem cell transplantation in myeloma, and it has been part of the therapeutic armamentarium for more than a decade. Early results were discouraging due to high transplantation-related mortality and high rates of graft-versus-host disease. More recently, better supportive care, increasing experience with this modality and its complications, use of reduced-intensity conditioning regimens, and its use earlier in the course of disease have led to improved outcomes. Patients with high-risk genetic and biochemical features do poorly with conventional therapies, and allogeneic transplantation offers the potential for long-term disease control.

Original languageEnglish (US)
Pages (from-to)99-106
Number of pages8
JournalCurrent Hematologic Malignancy Reports
Volume3
Issue number2
DOIs
StatePublished - Apr 1 2008

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Role of allogeneic stem cell transplantation in multiple myeloma'. Together they form a unique fingerprint.

  • Cite this